表紙
市場調査レポート

中国のリツキシマブ市場の分析

Investigation Report on China Rituximab Market, 2010-2019

発行 China Research and Intelligence 商品コード 296864
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
中国のリツキシマブ市場の分析 Investigation Report on China Rituximab Market, 2010-2019
出版日: 2015年05月28日 ページ情報: 英文 30 Pages
概要

リツキシマブ(Roche社「マブセラ」、Genentech社「リツキサン」)は、腫瘍の治療薬として1997年に承認された、CD20抗原に対するキメラ型モノクローナル抗体です。B細胞リンパ腫の治療に非常に有効で、良好な耐性を示しています。世界のリツキシマブ市場の売上高は、2010年が50億3,400万米ドル、2011年が61億4,000万米ドル、2012年が71億4,300万米ドルと、順調に推移し、2014には80億米ドルを超えました。

当レポートでは、中国におけるリツキシマブ市場について調査分析し、主要メーカーの市場シェア、病院市場での販売価格、病院市場での市場シェア(剤形別)、自己免疫疾患の発生率、ジェネリック医薬品の製造スケジュール、市場の見通しなどをお届けいたします。

第1章 リツキシマブの関連概念

  • 適応
  • 世界市場の販売状況

第2章 中国におけるリツキシマブの市場概要

  • 特許の状況
  • 主要メーカー
  • 市場規模

第3章 中国におけるリツキシマブの売上高の分析

  • 総売上高
  • 売上高:地域別

第4章 中国におけるリツキシマブの主要メーカーの市場シェアの分析

  • 市場シェア:売上高別
  • 市場シェア:販売量別

第5章 中国におけるリツキシマブ(剤形別)の市場規模の分析

  • 市場シェア:売上高・剤形別
  • 市場シェア:販売量・剤形別

第6章 中国の病院市場におけるリツキシマブの基準価格

  • Hoffmann-La Roche, Inc.
  • Roche Diagnostics
  • Shanghai Roche Pharmaceutical Co., Ltd.

第7章 中国におけるリツキシマブの主要メーカー

  • Hoffmann-La Roche, Inc.
  • Roche Diagnostics
  • Shanghai Roche Pharmaceutical Co., Ltd.

第8章 中国のリツキシマブ市場の見通し

  • 非ホジキンリンパ腫・自己免疫疾患の発生率の予測
  • リツキシマブの市場規模の予測
  • リツキシマブの競合パターンの予測

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 1505181

Rituximab (trade name is Rituxan by Roche) was a human-mouse chimeric anti-CD20 monoclonal antibody approved by FDA to treat tumor in 1997. The treatment range of Rituximab extends from B-cell malignant tumors to rheumatoid arthritis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura and such autoimmune diseases. In 2014, the sales revenue of Rituxan exceeded USD 8 billion.

In China, the incidence of non-Hodgkin lymphoma fast rises from 20/1 million at the end of 20 century to 70/1 million nowadays. Autoimmune diseases can harm central nervouos system and organs such as lung, liver and kidney, leading to organ dysfunction and even organ failure. All of them can be life threatening. Statistics shows that there are approximately 30 to 40 million people suffering from autoimmune diseases in China. Such incidence is high enough to attract people's attention.

By the second quarter of 2015, there is no Rituximab produced by Chinese domestic enterprise on the market. The market is wholly occupied by products of Roche. Early 2014, monoclonal antibody drug "recombinant human-mouse chimeric anti-CD20 monoclonal antibody injection" produced by Hisun was approved clinical. It is generic drug of Rituximab of Roche. Five manufacturers in China have reported clinical use of rituximab generic drug. It is estimated that more generic drugs will go on the market in the next few years. According to CRI's investigation on certain sample hospitals in China, the CAGR of sales value of rituximab surpassed 30% from 2005 to 2014. Rituximab is expected to have huge room to grow in future Chinese market.

Through this report, the readers can acquire the following information:

  • Market Share of Major Rituximab Manufacturers in China Sample Hospitals
  • Sales Price of Rituximab in China Hospital Market
  • Market Share of Rituximab by Dosage Form in China Hospital Market
  • Incidence of Autoimmune Diseases in China
  • Manufacturing Schedule of Rituximab Generic Drug
  • Prospect of China Rituximab Market

The Following Enterprises and People Are Recommended to Purchase This Report:

  • Manufacturers of Crude and Finished Monoclonal Antibody Remedy
  • Medical Institutions
  • Investors/Research Institutes Focusing on Monoclonal Antibody Market
  • CRI also provides custom research focusing on China monoclonal antibody market.

Table of Contents

1. Relevant Concepts of Rituximab

  • 1.1. Indication
  • 1.2. Sales Status on the Global Market

2. Market Overview of Rituximab in China, 2010-2014

  • 2.1. Patent Status
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Investigation on Sales Value of Rituximab in China, 2010-2014

  • 3.1. Total Sales Value
  • 3.2. Sales Value by Region

4. Investigation on Market Share of Major Rituximab Manufacturers in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Investigation on Market Size of Rituximab by Dosage Form in China, 2010-2014

  • 5.1. Market Share by Sales Value and Dosage Form
  • 5.2. Market Share by Sales Volume and Dosage Form

6. Reference Price of Rituximab in China Hospital Market, 2014

  • 6.1. Hoffmann-La Roche, Inc.
  • 6.2. Roche Diagnostics
  • 6.3. Shanghai Roche Pharmaceutical Co., Ltd.

7. Analysis on Major Rituximab Manufacturers in China

  • 7.1. Hoffmann-La Roche, Inc.
  • 7.2. Roche Diagnostics
  • 7.3. Shanghai Roche Pharmaceutical Co., Ltd.

8. Prospect of China Rituximab Market, 2015-2019

  • 8.1. Forecast on Incidence of non-Hodgkin lymphoma and Autoimmune Disease
  • 8.2. Forecast on Rituximab Market Size
  • 8.3. Forecast on Rituximab Competition Pattern

Selected Charts

  • Chart Rituximab Products Approved to Market in China, 2014
  • Chart Sales Value of Rituximab in Global Market, 2010-2014
  • Chart Sales Value of Rituximab in Hospital Market in China, 2010-2014
  • Chart Sales Value of Rituximab by Region in China, 2010-2014
  • Chart Market Share of Rituximab Enterprises by Sales Value in China, 2010-2014
  • Chart Price of Rituximab Produced by Hoffmann-La, Inc. in China Hospital Market
  • Chart Price of Rituximab Produced by Shanghai Roche in China Hospital Market
  • Chart Forecast on Market Size of Hospital-use Rituximab in China, 2015-2019
  • Chart Status Quo of Rituximab Generic Drug in China Market
Back to Top